CBPO 65.00 China Biologic Products $CBPO Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 3, 2014 at 10:39 PM

CBPO 65.00 China Biologic Products $CBPO Hit a 52 week high of 65.45 Closing the day 11/03/14 at 65.00 +4.75 +7.88% With a day low of 59.94 and a total volume of 102,978.

CBPO Recent Posts: http://investorshangout.com/China-Biologic-Pr...BPO-53617/

CBPO China Biologic Products Recent Headline News

China Biologic to Build Two New Plasma Collection Stations in Hebei Province
PR Newswire - Mon Nov 03, 7:02AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"

, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd. ("Shandong Taibang"

received on October 31, 2014 the approval from the Hebei Provincial Health and Family Planning Commission to build two new plasma collection stations in Hebei Province.
CBPO: 65.00 (+4.75)

China Biologic to Report Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"

, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release third quarter 2014 financial results on Wednesday, November 5, 2014 after the market closes.
CBPO: 65.00 (+4.75)

4 Stocks Spiking on Big Volume
at The Street - Thu Oct 23, 8:30AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
NFLX: 388.41 (-4.36), CBPO: 65.00 (+4.75), LMT: 190.75 (+0.18), TLLP: 57.50 (+1.20)

China Biologic to begin commercial manufacturing of human prothrombin complex concentrate at Shandong Taibang Facility
M2 - Mon Oct 20, 6:48AM CDT
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) disclosed on Friday the receipt of approval from the China Food and Drug Administration (the CFDA) for commercial manufacturing of human prothrombin complex concentrate (PCC) at its Shandong Taibang facility.
CBPO: 65.00 (+4.75)

China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility
PR Newswire - Fri Oct 17, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"

, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received approval from the China Food and Drug Administration (the "CFDA"

for commercial manufacturing of human prothrombin complex concentrate ("PCC"

at its Shandong Taibang facility. The CFDA inspected Shandong Taibang's new coagulation factor production facility for Good Manufacturing Practices ("GMP"

compliance in June 2013 and is expected to issue the GMP certificate before early December. The Company expects to commence commercial production of PCC at its Shandong Taibang facility immediately upon the receipt of the GMP certificate.
CBPO: 65.00 (+4.75)

Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 8:39AM CDT
Acceleron Pharma (XLRN) was a big mover last session, as its shares rose almost 13% on the day.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), XLRN: 34.15 (-2.83)

Sangamo Biosciences (SGMO) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:51AM CDT
Sangamo Biosciences Inc. (SGMO) was a big mover last session, as its shares rose over 5% on the day.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), SGMO: 11.61 (-0.53)

Global Eczema Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5txcp4/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - FAES Farma SA - China Biologic Products, Inc. - GlycaNova Norway AS - Immune Response BioPharma, Inc. Drug Profiles - bilastine - desloratadine - Drug for Atopic Dermatitis and Eczema - Varicella Hyperimmune Globulins - IR-444 - MM-1501 For more information visit http://www.researchandmarkets.com/research/5t...a_pipeline
CBPO: 65.00 (+4.75), MRK: 58.92 (+0.98)

OncoMed Pharmaceuticals (OMED) Jumps: Stock Up 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 7:51AM CDT
OncoMed Pharmaceuticals, Inc. (OMED) was a big mover last session, as its shares rose over 5% on the day.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), OMED: 20.44 (-0.33)

Integra to Buy Medtronic's MicroFrance, Xomed; Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:10PM CDT
Following this news, Integra's (IART) share price jumped 1.6% to eventually close at $49.76 on Friday.
CBPO: 65.00 (+4.75), IART: 51.49 (+0.38), CBM: 22.26 (+1.18), MDT: 68.15 (-0.01)

Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:39AM CDT
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as its shares rose over 6% on the day.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), CYTX: 0.49 (-0.03)

Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:51AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as its shares rose almost 7% on the day.
CBPO: 65.00 (+4.75), VRTX: 112.98 (+0.34), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02)

Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:20PM CDT
The FDA has lifted the clinical hold from a phase II study on Halozyme's (HALO) PEGPH20 in combination with modified FOLFIRINOX for advanced pancreatic cancer, which is being conducted by SWOG.
CBPO: 65.00 (+4.75), HALO: 9.50 (-0.12), CBM: 22.26 (+1.18), BAX: 69.68 (-0.46)

VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), VVUS: 3.31 (-0.08)

Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
CBPO: 65.00 (+4.75), BIIB: 321.25 (+0.17), CBM: 22.26 (+1.18), ARNA: 4.22 (-0.14)

ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:58AM CDT
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose nearly 9% on the day.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), IMUC: 0.68 (-0.02)

Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
CBPO: 65.00 (+4.75), HALO: 9.50 (-0.12), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02)

Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:30PM CDT
Regeneron Pharmaceuticals' (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), REGN: 395.26 (+1.54)

Should You Get Rid of Vital Therapies (VTL) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 7:53AM CDT
Vital Therapies is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), VTL: 17.35 (+0.09)

Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:00PM CDT
Currently, Genomic Health (GHDX) is focused on boosting its Oncotype DX portfolio in the international market
CBPO: 65.00 (+4.75), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02), GHDX: 35.96 (-0.38)

China Biologic Products Inc. (CBPO) Stock Research Links

CBPO Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Wuhan Colposcopy Course Advances Non-Invasive Treatments

Wuhan's Leap in Colposcopy Training Innovation Talk about shaking things up in the medical world—this 2026 CSCCP-ASCCP Colposcopy Training Course in Wuhan isn't just another run-of-the-mill gathering. It's a heavyweight clash of brainpower between the Chinese and American medical pros in the relentless battle against cervical lesions. But here's where it gets spicy: for...

SOCaaS Market Grows to $16.68B by 2031, What It Means

SOC as a Service: More Than Just Jargon The term 'SOC as a Service' (SOCaaS) might sound like some alphabet soup, but it’s a serious contender in today’s digital security world. With projected growth from $9.04 billion in 2026 to a whopping $16.68 billion by 2031, the SOCaaS market isn’t just having a moment, it’s setting up a stage for the long haul. It’s like...

Middle East's Premier Jewellery Event: A Game-Changer

An Event Gemmed with Strategic Importance The Middle East is about to see its streets glitter even more than usual. Next week, the Jewellery, Gem & Technology in Dubai (JGTD) event rolls into town, packed with brands that’ll drop in like swanky diamonds. We’re talking 300 heavy-duty exhibitors from all corners of the globe, ready to strut their stuff at the DEC Expo...

Dimethylaminopropylamine Market Eyes $732M by 2035

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

PZZA Faces Class Action: Strategic Shake-up or Misstep?

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Hexagon Composites to Release Q3 2026 Results Soon

Anticipating Hexagon's Third Quarter 2026 Results Hexagon Composites ASA, based out of Oslo, Norway, is setting the stage to release its third quarter 2026 financial results. Mark your calendars for November 6, 2026, at the early bird hour of 07:00 am CET. For those of us keen on dissecting the numbers, that's when the real action begins. Executive Insights Await A...

Astra Security Tackles PHP2Shell Vulnerabilities Head-On

Unlocking the PHP Puzzle Hot off the press, Astra Security's stepping up to the plate with some freebie tools designed to sniff out and stamp out those pesky PHP2Shell vulnerabilities—CVE-2026-109618 and CVE-2026-109619. If you're not familiar, these suckers rate a whopping 9.2 on the CVSS v4.0 scale, and that means they got the potential to let remote code execution...

OwnATC Empowers Trainers to Expand Access to Care

The Untapped Potential of Athletic Trainers In a hustle to get people's bodies moving and grooving right, we often overlook a crucial player: the Certified Athletic Trainer (CAT). These folks have been shelved in schools or sports arenas for far too long, especially when their expertise could be lighting up communities across the map. Enter OwnATC, shaking things up. A...

NorthStar Anesthesia Focuses on ASC Partnerships

NorthStar's Growing Partnerships Amid Operational Woes Anesthesia isn’t always the first thing you’d think of in big market-moving terms, but when it comes to keeping ambulatory surgery centers (ASCs) afloat, it might just be the critical stitch. ASCs are getting pinched from all sides—rising costs, staffing nightmares, and those unexpected surgical disruptions that...